Tigulixostat
A pharmaceutical drug used in the treatment of gout
| Tigulixostat | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Tigulixostat is a pharmaceutical drug that is currently under investigation for the treatment of gout, a form of arthritis characterized by recurrent attacks of a red, tender, hot, and swollen joint. It is a novel non-purine selective inhibitor of xanthine oxidase, an enzyme involved in the production of uric acid.
Mechanism of Action[edit | edit source]
Tigulixostat works by inhibiting the activity of xanthine oxidase, an enzyme that plays a crucial role in the conversion of hypoxanthine to xanthine and then to uric acid. By reducing the production of uric acid, tigulixostat helps to lower serum urate levels, thereby reducing the risk of gout attacks.
Clinical Development[edit | edit source]
Tigulixostat is currently undergoing clinical trials to evaluate its efficacy and safety in patients with gout. Preliminary studies have shown that it effectively reduces serum urate levels and is well-tolerated by patients. The drug is being developed as an alternative to existing xanthine oxidase inhibitors such as allopurinol and febuxostat.
Potential Benefits[edit | edit source]
The development of tigulixostat is significant because it offers a potential new treatment option for patients who are intolerant to or inadequately treated by existing therapies. Its selective inhibition of xanthine oxidase may result in fewer side effects compared to non-selective inhibitors.
Side Effects[edit | edit source]
As with any medication, tigulixostat may cause side effects. Common side effects observed in clinical trials include mild gastrointestinal disturbances, headache, and dizziness. However, the overall safety profile of tigulixostat is still being evaluated in ongoing studies.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
